S17 Ep34: As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD episode artwork

EPISODE · Jun 18, 2026 · 13 MIN

S17 Ep34: As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

from OncLive® On Air · host OncLive® On Air

In today’s episode, we welcomed Brad Haverkos, MD, to discuss evolving management and treatment adherence strategies in cutaneous T-cell lymphoma (CTCL). Dr Haverkos is an associate professor of medicine-hematology at the University of Colorado in Anschutz School of Medicine in Aurora. In the exclusive interview, Dr Haverkos outlined treatment approaches across early-stage and advanced CTCL, identified strategies for identifying disease progression in this patient population, and spoke about how clinicians manage mogamulizumab-kpkc (Poteligeo)-associated rash.

Episode metadata supplied by the publisher feed · Published Jun 18, 2026

Embed this episode

Brad Haverkos, MD, discusses evolving management and treatment adherence strategies in cutaneous T-cell lymphoma.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

S17 Ep34: As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

0:00 13:14

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 13 minutes long.

When was this OncLive® On Air episode published?

This episode was published on June 18, 2026.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!